Register for our free email digests:
Latest From Roche
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.
AstraZeneca started the greatest number of clinical studies in 2016, finds Trialtrove's latest review, but a new kid on the block, the Chinese company Jiangsu Hengrui Medicine, is nipping at the heels of big pharma in the lists of busiest trial starters.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Intelliject Inc.
- North America
- Parent & Subsidiaries
- kaleo Inc.
- Senior Management
T. Spencer Williamson, IV, Pres. & CEO
Christopher T Schools, CFO
Kristopher D Ford, VP, Bus. Dev.
Eric Edwards, MD, PhD, VP, R&D & CMO
- Contact Info
Phone: (804) 545-6360
111 Virginia St.
Richmond, VA 23219
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.